 Ampio Pharmaceuticals, Inc. NYSE American: AMPE; the Company, a pre-revenue development stage biopharmaceutical company announced today that it has suspended patient enrollment in its Phase 3 clinical trial of Ampion AP-013 for the treatment of severe osteoarthritis of the knee OAK. The trial focuses on individuals with the most severely diseased OAK, which represents an underserved patient population typically excluded from clinical studies because of the intractable nature of their condition. The average and maximum age of a patient in the AP-013 clinical trial is 65 and 87 years old, respectively. The Centers for Disease Control and Prevention CDC have indicated that older adults, 65 years and older, are at higher risk for severe illness during the current COVID-19 pandemic. 